Patents by Inventor Jeffrey Norman Crabb

Jeffrey Norman Crabb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds
    Patent number: 8436167
    Abstract: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: May 7, 2013
    Assignee: AstraZeneca UK Limited
    Inventors: Rebecca Jane Booth, Peter Anthony Cittern, Jeffrey Norman Crabb, John Horbury, David Wyn Calvert Jones
  • Crystalline Form of Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoicacid] Calcium Salt
    Publication number: 20120059022
    Abstract: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.
    Type: Application
    Filed: March 1, 2011
    Publication date: March 8, 2012
    Inventors: Rebecca Jane Booth, Peter Anthony Cittern, Jeffrey Norman Crabb, John Horbury, David Wyn Calvert Jones
  • Production of rosuvastatin calcium salt
    Patent number: 8063213
    Abstract: An improved process for the manufacture of (E)-7-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsulfony)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, Formula (1), which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis, is described.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: November 22, 2011
    Assignee: AstraZeneca UK Limited
    Inventors: Jeffrey Norman Crabb, John Horbury, Nigel Phillip Taylor
  • PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES
    Publication number: 20100228028
    Abstract: A process for the manufacture of a compound of formula (V), useful for making rosuvastatin, by a stereoselective aldol reaction is described. Novel intermediates and processes to make them are also described.
    Type: Application
    Filed: July 3, 2006
    Publication date: September 9, 2010
    Inventors: Michael Butters, David Kenneth Cox, Jeffrey Norman Crabb, Steven Robert Lenger, Paul Michael Murrray, Evan William Snape
  • Crystalline Form of Bis [(E)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2-[methyl(methyl-sulfonyl)amino] pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] Calcium Salt
    Publication number: 20100222373
    Abstract: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 2, 2010
    Applicant: AstarZeneca UK Limited
    Inventors: Rebecca Jane Booth, Peter Anthony Cittern, Jeffrey Norman Crabb, John Horbury, David Way Calvert Jones
  • Production of Rosuvastatin Calcium Salt
    Publication number: 20080221323
    Abstract: An improved process for the manufacture of (E)-7-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsulfony)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, Formula (1), which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis, is described.
    Type: Application
    Filed: June 3, 2004
    Publication date: September 11, 2008
    Inventors: Jeffrey Norman Crabb, John Horbury, Nigel Phillip Taylor